Omnicell Inc. (OMCL) Stake Raised by Emerald Advisers Inc. PA
Emerald Advisers Inc. PA raised its stake in Omnicell Inc. (NASDAQ:OMCL) by 266.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 134,300 shares of the company’s stock after buying an additional 97,630 shares during the period. Emerald Advisers Inc. PA’s holdings in Omnicell were worth $4,597,000 at the end of the most recent reporting period.
A number of other institutional investors have also added to or reduced their stakes in OMCL. Eqis Capital Management Inc. raised its stake in shares of Omnicell by 11.9% in the second quarter. Eqis Capital Management Inc. now owns 9,163 shares of the company’s stock valued at $314,000 after buying an additional 971 shares in the last quarter. Capstone Asset Management Co. raised its stake in shares of Omnicell by 7.9% in the second quarter. Capstone Asset Management Co. now owns 13,693 shares of the company’s stock valued at $469,000 after buying an additional 1,000 shares in the last quarter. Aperio Group LLC raised its stake in shares of Omnicell by 10.9% in the first quarter. Aperio Group LLC now owns 13,132 shares of the company’s stock valued at $366,000 after buying an additional 1,288 shares in the last quarter. Thomson Horstmann & Bryant Inc. raised its stake in shares of Omnicell by 2.0% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 156,771 shares of the company’s stock valued at $5,366,000 after buying an additional 3,021 shares in the last quarter. Finally, Zebra Capital Management LLC raised its stake in shares of Omnicell by 24.6% in the first quarter. Zebra Capital Management LLC now owns 17,102 shares of the company’s stock valued at $477,000 after buying an additional 3,379 shares in the last quarter. Hedge funds and other institutional investors own 95.26% of the company’s stock.
Omnicell Inc. (NASDAQ:OMCL) traded down 0.30% on Friday, reaching $36.79. The company’s stock had a trading volume of 165,963 shares. The stock’s 50 day moving average is $37.88 and its 200-day moving average is $33.96. The firm has a market capitalization of $1.33 billion, a PE ratio of 93.38 and a beta of 0.58. Omnicell Inc. has a 52 week low of $25.06 and a 52 week high of $40.50.
Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.38 EPS for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.06. Omnicell had a net margin of 2.36% and a return on equity of 10.41%. The company earned $175.60 million during the quarter, compared to the consensus estimate of $170.89 million. During the same period in the prior year, the business posted $0.28 EPS. The company’s quarterly revenue was up 55.7% on a year-over-year basis. Analysts predict that Omnicell Inc. will post $1.58 EPS for the current year.
A number of research firms have recently issued reports on OMCL. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $46.00 target price on shares of Omnicell in a research note on Tuesday, September 13th. Sidoti lowered Omnicell from a “buy” rating to a “neutral” rating and set a $43.00 target price for the company. in a research note on Thursday, September 8th. Zacks Investment Research lowered Omnicell from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, August 3rd. Finally, FBR & Co increased their target price on Omnicell from $40.00 to $41.00 and gave the company an “outperform” rating in a research note on Friday, July 29th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $38.13.
In other news, Director Gary S. Petersmeyer sold 2,000 shares of the stock in a transaction dated Monday, September 12th. The shares were sold at an average price of $37.98, for a total transaction of $75,960.00. Following the completion of the transaction, the director now directly owns 17,987 shares in the company, valued at approximately $683,146.26. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Jorge R. Taborga sold 10,023 shares of the stock in a transaction dated Friday, July 29th. The stock was sold at an average price of $40.00, for a total transaction of $400,920.00. Following the transaction, the vice president now owns 49,073 shares of the company’s stock, valued at $1,962,920. The disclosure for this sale can be found here. Insiders own 3.75% of the company’s stock.
Omnicell Company Profile
Omnicell, Inc (Omnicell) is a provider of automation and business information solutions designed to enable healthcare systems to streamline the medication administration process and manage medical supplies for increased operational efficiency and enhanced patient safety. The Company operates through two operating segments: Automation and Analytics, and Medication Adherence.
Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell Inc. (NASDAQ:OMCL).
Receive News & Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related companies with MarketBeat.com's FREE daily email newsletter.